Trans Genic, Inc.

Detailed Description

Trans Genic Inc. develops, distributes, and licenses genetically engineered animals and antibodies in Japan. The company provides information of approximately 750 knockout mouse strains; 2,000 knockout ES clones produced by the exchangeable gene-trap method; 900 knockout mouse strains, as well as 750 phenotypic data centering on target genes for drug discovery. It also engages in the custom production of genetically engineered mice comprising conventional, conditional, and knock-in mice, as well as transgenic mice; and customized mouse-related analysis, such as speed congenics and phenotype analysis, including blood examination, as well as cryopreservation of embryo and sperm, and housing and breeding activities. In addition, the company provides mouse-related products, such as circadian locomotor output cycles kaput mice used as disease models; frozen embryos used to produce genetically engineered mice; and electronic instruction manual of reproduction technology for embryo manipulation, as well as approximately 600 antibody products. Further, it offers contract services for drug efficiency and pharmacological, safety pharmacological, disposition, and pharmacokinetic studies. Additionally, the company provides drug discovery support services, such as clinical and nonclinical pharmacological tests for Parkinson's and Alzheimer's diseases; and high density human tissue microarrays for use in the assessment of drug target molecules. It is also involved in the custom production of high-affinity, monoclonal, and polyclonal antibodies; and protein hyper-producing cells, as well as the provision of antibody purification and labeling, and peptide synthesis services. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was founded in 1998 and is headquartered in Fukuoka, Japan.